Short Interest in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Rises By 102.7%

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 134,600 shares, a growth of 102.7% from the December 15th total of 66,400 shares. Approximately 2.2% of the company’s stock are short sold. Based on an average trading volume of 3,450,000 shares, the short-interest ratio is currently 0.0 days.

Cyclacel Pharmaceuticals Stock Performance

Shares of NASDAQ CYCC traded down $0.01 during midday trading on Thursday, hitting $0.35. The company’s stock had a trading volume of 281,838 shares, compared to its average volume of 12,324,971. The firm has a market cap of $2.22 million, a P/E ratio of -0.04 and a beta of 0.35. Cyclacel Pharmaceuticals has a 1-year low of $0.31 and a 1-year high of $4.00. The firm’s fifty day moving average price is $0.38 and its 200-day moving average price is $0.91.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last announced its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.36. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned about 9.18% of Cyclacel Pharmaceuticals as of its most recent SEC filing. 23.58% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on CYCC shares. Roth Capital lowered shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. StockNews.com initiated coverage on Cyclacel Pharmaceuticals in a report on Friday, January 10th. They set a “sell” rating on the stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.